Introduction
============

Endometrial cancer (EC) is the most commonly occurring malignant neoplasm of the female reproductive tract in developed countries ([@b1-ol-0-0-6592]). Typically, EC is confined to the uterus and is characterized by a good prognosis, with an overall 5-year survival rate of 75--80% ([@b2-ol-0-0-6592]). Endometrial endometrioid cancer (EEC), a histological subtype of EC, represents 80% of all cases of EC ([@b2-ol-0-0-6592]).

Adenomyosis uteri (AM) is defined by the presence of endometrial mucosa within the myometrium. In hysterectomy specimens obtained during the treatment of EEC, AM may be found in 16--42% ([@b3-ol-0-0-6592]--[@b6-ol-0-0-6592]). A more favorable prognosis and a lower histopathological grade in cases EEC with coexisting AM has been reported in a number of studies ([@b3-ol-0-0-6592],[@b4-ol-0-0-6592],[@b7-ol-0-0-6592],[@b8-ol-0-0-6592]). However the significance of the presence of AM in cases of EEC remains unclear. Despite early predictions, the collective evidence suggests that estrogen receptor β (ERβ) serves an important role in normal endometrial tissue ([@b9-ol-0-0-6592]--[@b11-ol-0-0-6592]) and also in most, if not all, benign and malignant endometrial diseases ([@b12-ol-0-0-6592]--[@b14-ol-0-0-6592]). In ectopic endometrial lesions and AM, it has been reported that high levels of ERβ expression, 100-times higher than that in eutopic endometrium, may be detected ([@b15-ol-0-0-6592]). In EEC, it has been reported that ERβ mRNA and protein levels are decreased compared with adjacent normal endometrium or normal proliferative endometrium from healthy premenopausal women ([@b16-ol-0-0-6592],[@b17-ol-0-0-6592]). However, a potential oncogenic role of ERβ has also been proposed in other reports, which showed an upregulation of the ERβ5 transcript in high-grade EEC ([@b18-ol-0-0-6592],[@b19-ol-0-0-6592]). In summary, ERβ appears to play a dual role: As a tumour suppressor in healthy endometrium, and as a potential tumour promoter in high-grade EC cells that have lost other receptor subtypes ([@b12-ol-0-0-6592]).

The present study aimed to identify the differences in the expression of several proteins, including ERβ, in cases of EEC with and without AM, and to evaluate the potential histopathological and prognostic distinctions between these two groups.

Patients and methods
====================

### Patients and specimen characteristics

The present retrospective observational cohort study included 57 patients with EEC, whose records were obtained from the archives of the Department of Obstetrics and Gynaecology, Ludwig-Maximilian University of Munich (Munich, Germany). Group A consisted of 22 patients with coexistent EEC and AM. Group B comprised 35 patients with EEC alone. Patients had undergone surgical resection of EEC between January 1990 and December 2002. The patients\' former tumour stages were corrected to the updated FIGO classification from 2010 ([@b20-ol-0-0-6592]).

### Study design

Patients were recruited between 1990 and 2002 as described; follow-up continued until December 2015. Clinical and follow-up data were retrieved retrospectively from patient charts and from the Munich Cancer Registry (Munich, Germany). The overall mean follow-up time of the cohort was 8 years (range, 4--15 years). The outcomes assessed were overall survival time and progression free survival. Overall survival is defined as the number of months between the patient\'s initial diagnosis with endometrial carcinoma until the last follow up or mortality. Progression free survival is defined by the number of months between the initial diagnosis and when the patient developed either a relapse or further progression of the disease, including lymph node involvement or metastasis.

### Ethical approval

All patient data were fully anonymized, and the study was performed according to the standards set in the Declaration of Helsinki, 1975. All tumour tissue used in the study was leftover material that had initially been collected for histopathological diagnostic assessments. All diagnostic procedures had already been fully completed when samples were retrieved for the study. The present study was approved by the Ethics Committee of the Ludwig-Maximilian University of Munich (approval no. 449-14). Investigators were blinded to the patients\' clinical information during experimental analysis.

### Assay methods

Formalin-fixed, paraffin-embedded tissue sections were stored at room temperature. Tumour tissues and tissues with AM were selected from hematoxylin-stained whole uterus slides. Sections with a thickness of 2 µm of tumour or AM positive tissue were prepared and used for the staining. Slides were dewaxed in xylol and rehydrated in a descending series of alcohol concentrations. The immunohistochemical staining of the paraffin-embedded tissues for glycodelin (in Group B) and inhibin βB was detected with the avidin-biotin complex method described by Kricka and Wild ([@b21-ol-0-0-6592]) using the mouse VECTASTAIN Elite ABC kit (Vector Laboratories, Inc., Burlingame, CA, USA). For the detection of glycodelin (in Group A) and ERβ1, the ZytoChem Plus HRP Polymer kit (Zytomed Systems GmbH, Berlin, Germany) was used, according to the manufacturer\'s protocol. The primary antibodies are described in [Table I](#tI-ol-0-0-6592){ref-type="table"}, and were incubated with the tissue sections for 16 h at 4°C, prior to detection with the aforementioned methods.

Immunoreactivity was quantified with Remmele\'s semi-quantitative immunoreactivity score (IRS) ([@b22-ol-0-0-6592]) by two independent observers by consensus. This scoring method quantifies immunoreactivity by multiplication of the optical staining intensity score (0, none; 1, weak; 2, moderate; or 3, strong) with a score representing the percentage of positively stained cells (0, no staining; 1, ≤10% of cells; 2, 11--50% of cells; 3, 51--80% of cells; or 4, ≥81% of cells), resulting in the overall IRS, which can be subdivided as follows: 0--2, negative; 3--4, weak-positive; 6--8, moderate-positive; and 9--12, strong-positive.

### Statistical analysis

The IBM statistical package SPSS (version 23; IBM, Armonk, NY, USA) was used to test data for statistical significance. A Mann-Whitney U-Test was performed for analyses of differences in staining results and Spearman\'s rank correlation analysis was performed for correlation analyses. Survival times were compared by using Kaplan-Meier estimates, and the differences in the patients\' overall survival rates were tested for significance by using the log-rank test. Data were considered to be statistically significantly different where P\<0.05.

Results
=======

### General patient features

The patients in Group A (AM and EEC) and Group B (EEC only) were similar in age at time of EEC diagnosis (mean age, 63.9 vs. 63.2 years, respectively). With regard to the prevalence of diabetes, hypertension or obesity in the patients\' medical histories, there were no significance differences between the groups. The clinicopathological characteristics and follow-up data of all included patients are reported in detail in [Table II](#tII-ol-0-0-6592){ref-type="table"}.

### AM is associated with lower FIGO stage in EEC

In the current cohort, the surgical FIGO stage differed significantly between the two groups. In Group A (AM and EEC), 22/22 patients (100%) were assigned to FIGO stage I, compared with 28/35 patients (80%) in Group B (EEC only; P=0.002). Notably, 86.4% (19/22 patients) of Group A and 51.4% (18/35 patients) of Group B were categorized as stage IA. In Group B, 3/35 patients (8.6%) were assigned to FIGO stage II, and 4/35 patients (11.4%) were assigned to FIGO stage III.

### AM is associated with a lower grade in EEC

With regard to the prevalence of lymphatic or vascular invasion, no significant differences between the two groups could be identified. Regarding tumour grade, a significant difference was identified between Group A and Group B (G1, 90.9 vs. 45.7%; G2, 4.5 vs. 51.4%; G3, 0 vs. 2.9%, respectively; P=0.001; [Fig. 1](#f1-ol-0-0-6592){ref-type="fig"}). Thus, higher tumour grades, indicating poor differentiation of the tumour cells, were more common in the patients without AM.

### AM is associated with increased survival time in patients with EEC

The survival curves of the patients in Groups A and B are shown in [Fig. 2](#f2-ol-0-0-6592){ref-type="fig"}. The 5-year overall survival rate of Group A was 95%, which was significantly higher than that of Group B (82%; P=0.024). The survival rate after 10 years remained the same for Group A, whereas the 10-year survival rate of Group B decreased to 72%. The mean overall survival time was higher in Group A than in Group B (159 months (13.25 years) vs. 142 months (11.8 years), respectively). In summary, patients with AM and EEC (Group A) had a significantly increased mean overall survival times than patients with EEC alone (Group B; P=0.024).

AM is associated with increased expression of ERβ and decreased expression of glycodelin in EEC. [Table III](#tIII-ol-0-0-6592){ref-type="table"} summarizes the results of the different protein expression analyses. When comparing the percentage of cases with an IRS \>2 for ERβ, a significant difference was identified between the two groups (P\<0.001): In Group B, ERβ expression was detected in 6/35 cases (17.1%), and only 1 case (2.9%) was assigned an IRS \>2 ([Fig. 3](#f3-ol-0-0-6592){ref-type="fig"}); whereas, in Group A, 14/20 cases assessed for ERβ expression (70%) exhibited expression of ERβ, with 6 cases (30%) assigned an IRS \>2 ([Fig. 4](#f4-ol-0-0-6592){ref-type="fig"}). Therefore, the presence of AM in cases of EEC is associated with higher expression of ERβ than that in cases of EEC alone. In Group A, the prevalence of glycodelin expression with an IRS \>2 was significantly lower (P=0.028; [Fig. 5](#f5-ol-0-0-6592){ref-type="fig"}) than that in Group B ([Fig. 6](#f6-ol-0-0-6592){ref-type="fig"}; [Table III](#tIII-ol-0-0-6592){ref-type="table"}). With regard to the prevalence of inhibin βB expression (data not shown), no significant differences between the two groups were identified (P=0.077).

Discussion
==========

The majority of cases of EC (80%) are of the endometrioid subtype (EEC) ([@b2-ol-0-0-6592]). This Type I EC is estrogen-dependent, is typically well-differentiated, and is characterized by a good prognosis in general. By contrast, Type II EC is estrogen-independent, predominantly comprises the serous and clear cell histological subtypes, and has a worse prognosis ([@b23-ol-0-0-6592]--[@b26-ol-0-0-6592]).

AM is a benign disease characterized by the presence of endometrial mucosa within the myometrium. It is a hormone-dependent disease and typically regresses subsequent to menopause. In postmenopausal women with EEC, there is a higher prevalence of AM and myoma uteri than in patients of the same age with uterine prolapse ([@b27-ol-0-0-6592]). Certain studies have reported a more favorable prognosis and a lower histopathological grade in cases of EEC with coexisting AM ([@b3-ol-0-0-6592],[@b4-ol-0-0-6592],[@b7-ol-0-0-6592],[@b8-ol-0-0-6592]).

Regarding the tumour stage, all 22 patients in Group A (AM and EEC; 100%) vs. only 28/35 patients (80%) in Group B (EEC only) were assigned to FIGO stage I (P=0.02). Additionally, a higher percentage of patients in Group A, compared with Group B, were assigned to FIGO stage IA (86.4 vs. 51.4%). These findings are in accord with the findings of studies by Musa *et al* ([@b28-ol-0-0-6592]) and Gizzo *et al* ([@b7-ol-0-0-6592]), which reported that concurrent AM and EEC was associated with a lower tumour grade, with \<50% myometrial invasion, and with the absence of lymphovascular space involvement and lymph node metastasis. Furthermore, the lower histopathological grade (G1, 90.9 vs. 45.7%, respectively) in Group A (with AM) vs. Group B (without AM) observed in the present study was consistent with the report by Koshiyama *et al* ([@b8-ol-0-0-6592]). Thus, the present study confirmed that patients with coexisting AM and EEC tend to have a lower tumour stage and a higher differentiation grade. One possible explanation for this finding could be that there is an adhesion mechanism between AM foci and cancer cells; these adhesions may prevent cancer cells from invading deeper in the myometrium ([@b29-ol-0-0-6592]--[@b31-ol-0-0-6592]). Regarding the survival data, patients with EEC and coexistent AM showed significantly more favorable outcomes than those with EEC alone.

Although previous studies have investigated ERβ, glycodelin and inhibin βB in cases of AM and EEC ([@b31-ol-0-0-6592]--[@b35-ol-0-0-6592]), to the best of our knowledge, the present study is the first in which these factors were measured and compared with one other in a single study. Regarding the expression of ERβ, Group A (AM and EEC) showed a significantly increased prevalence compared with Group B (EEC). This result may be explained by the increased expression of ERβ that has been shown to be present in AM ([@b15-ol-0-0-6592]). The decreased expression of ERβ in patients with EEC alone was also consistent with previous studies ([@b16-ol-0-0-6592],[@b17-ol-0-0-6592]).

Glycodelin, also known as a progestogen-associated endometrial protein, is a glycoprotein that has immunosuppressive capacity, and is predominantly produced in reproductive tissues ([@b36-ol-0-0-6592]). In a former study by our group, intermediate and high expression levels of glycodelin were associated with a prolonged survival time in patients with EC ([@b33-ol-0-0-6592]). Notably, in the current study, the prevalence of glycodelin expression in Group A (AM and EEC) was significantly decreased compared with that in Group B (EEC; P=0.028). This can be explained because women with endometriosis exhibited a \>50-fold downregulation of glycodelin in endometrial tissue compared to normal controls during the window of implantation ([@b37-ol-0-0-6592]). This decreased glycodelin expression also seemed to persist during the carcinogenesis of EC in the present study. In this context, women with AM and EEC appear to have a survival advantage, which could be explained by the angiogenic role of glycodelin during tumorigenesis; Song *et al* ([@b38-ol-0-0-6592]) found that a synthetic peptide derived from the sequence of glycodelin may serve an important role in neovascularization during embryogenesis and tumour development. It is notable that the inverse association between the presence of AM and the expression of glycodelin in EEC has only been identified in specimens that were stained with an antibody raised against a peptide sequence of glycodelin, and not in those that were stained with anti-glycodelin A antibody, which is specific to a particular glycosylated form of glycodelin ([@b39-ol-0-0-6592]--[@b41-ol-0-0-6592]). The measurement of glycodelin or ERβ was previously described in endometrial tissue ([@b42-ol-0-0-6592],[@b43-ol-0-0-6592]). However, no correlation between these two parameters has been described.

Inhibins are heterodimers consisting of an α subunit and a β subunit, and they belong to the transforming growth factor β cytokine family ([@b44-ol-0-0-6592]). The α subunit can dimerize with either βA or βB to form inhibin A (α-βA) or B (α-βB) ([@b45-ol-0-0-6592],[@b46-ol-0-0-6592]). In a previous study by our group, hyperplastic endometrial tissue was found to exhibit more intense staining for inhibins, particularly inhibin βA and βB, compared with EC. The presence of inhibin βA and βB suggests that they have an important function in endometrial pathogenesis and in endometrial carcinogenesis ([@b34-ol-0-0-6592]). For inhibin βB, more intense labelling was noted in atypical hyperplasia compared with EC ([@b34-ol-0-0-6592]). Thus, the present study investigated the differences in the expression of inhibin βB between the two groups. However, no significant differences were observed. In adenosquamous EC, the absence of the expression of inhibin βB and ERβ indicates the malignancy of these tumors ([@b32-ol-0-0-6592]).

One limitation of the present study was the variation in immunostaining in each specimen due to varying expression levels in different regions of the tumour. Other molecular methods for determining expression levels, such as western blotting, would be desirable to verify the results. However, as the present study utilized formalin-fixed, paraffin-embedded tissue specimens, this was not possible.

In conclusion, in cases of EEC, the presence of AM is associated with a lower FIGO stage, lower tumour grade and an increased survival rate. The expression of ERβ was more prevalent in cases of AM and EEC than in cases of EEC alone, whereas glycodelin expression was less prevalent when AM was present. Future research should focus on the influence of estrogen on the AM and EEC cases, and on prevention strategies in the development of EEC.
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![ERβ expression in Group B (patients with endometrioid endometrial cancer only). Representative photomicrographs of ERβ immunohistochemical staining are shown (immunoreactivity score, 0). ERβ, estrogen receptor β.](ol-14-03-3302-g02){#f3-ol-0-0-6592}

![ERβ expression in Group A (patients with endometrioid endometrial cancer and adenomyosis uteri). Representative microphotographs of ERβ immunohistochemical staining are shown (immunoreactivity score, 2). ERβ, estrogen receptor β.](ol-14-03-3302-g03){#f4-ol-0-0-6592}

![Glycodelin expression in Group A (patients with endometrioid endometrial cancer and adenomyosis uteri). Representative microphotographs of glycodelin immunohistochemical staining are shown (immunoreactivity score, 4).](ol-14-03-3302-g04){#f5-ol-0-0-6592}

![Glycodelin expression in Group B (patients with endometrioid endometrial cancer only). Representative microphotographs of glycodelin immunohistochemical staining are shown (immunoreactivity score, 6).](ol-14-03-3302-g05){#f6-ol-0-0-6592}

###### 

Primary antibodies used in the study.

  Primary antibody        Host            Clone     Cat. no.    Supplier                                                 Dilution
  ----------------------- --------------- --------- ----------- -------------------------------------------------------- --------------------------------
  Estrogen receptor β 1   Mouse (IgG2a)   PPG5/10   M7292       Dako; Agilent Technologies GmbH, Waldbronn, Germany      1:200 in Dako antibody diluent
  Glycodelin              Mouse (IgG1κ)   6F2       116--0646   Zytomed Systems GmbH, Berlin, Germany                    1:4,000 in PBS
  Inhibin βB              Mouse (IgG2a)   C5        MCA1661     Serotec; Bio-Rad Laboratories, Inc., Hercules, CA, USA   1:70 in Dako antibody diluent

###### 

General features, histological features and follow-up data of the patients in the two study groups.

  Characteristic                      All patients (n=57)   Group A^[a](#tfn1-ol-0-0-6592){ref-type="table-fn"}^ (n=22)   Group B^[b](#tfn2-ol-0-0-6592){ref-type="table-fn"}^ (n=35)   P-value
  ----------------------------------- --------------------- ------------------------------------------------------------- ------------------------------------------------------------- ---------
  Age at diagnosis, years                                                                                                                                                               0.987
    Mean                              63.5                  63.9                                                          63.2                                                          
    Range                             36--83                52--82                                                        36--83                                                        
  Obesity, n (%)                                                                                                                                                                        0.583
    Yes                               18 (31.6)             6 (27.3)                                                      12 (34.3)                                                     
    No                                39 (68.4)             16 (72.7)                                                     23 (65.7)                                                     
  Diabetes, n (%)                                                                                                                                                                       0.946
    Yes                               8 (14.0)              3 (13.6)                                                      5 (14.3)                                                      
    No                                49 (86.0)             19 (86.4)                                                     30 (85.7)                                                     
  Hypertension, n (%)                                                                                                                                                                   0.703
    Yes                               19 (33.3)             8 (36.4)                                                      11 (31.4)                                                     
    No                                38 (66.7)             14 (63.6)                                                     24 (68.6)                                                     
  FIGO stage, n (%)                                                                                                                                                                     0.002
    I                                 50 (87.7)             22 (100)                                                      28 (80.0)                                                     
    IA                                37 (64.9)             19 (86.4)                                                     18 (51.4)                                                     
    IB                                13 (22.8)             3 (13.6)                                                      10 (28.6)                                                     
    II                                3 (5.3)               0 (0.0)                                                       3 (8.6)                                                       
    III                               4 (7.0)               0 (0.0)                                                       4 (11.4)                                                      
    IV                                0 (0.0)               0 (0.0)                                                       0 (0.0)                                                       
  Lymph node metastasis, n (%)        2 (3.5)               1 (4.5)                                                       1 (2.9)                                                       
  Distant metastasis, n (%)           0 (0.0)               0 (0.0)                                                       0 (0.0)                                                       
  Grade, n (%)                                                                                                                                                                          0.001
    1                                 36 (63.2)             20 (90.9)                                                     16 (45.7)                                                     
    2                                 19 (33.3)             1 (4.5)                                                       18 (51.4)                                                     
    3                                 1 (1.8)               0 (0.0)                                                       1 (2.9)                                                       
  Lymphatic invasion, n (%)                                                                                                                                                             0.849
    Yes                               3 (5.3)               1 (4.5)                                                       2 (5.7)                                                       
    No                                54 (94.7)             21 (95.5)                                                     33 (94.3)                                                     
  Vascular invasion, n (%)                                                                                                                                                              0.428
    Yes                               1 (1.8)               0 (0.0)                                                       1 (2.9)                                                       
    No                                56 (98.2)             22 (100)                                                      34 (97.1)                                                     
  Follow-up duration, years                                                                                                                                                             
    Mean                              --                    8.9                                                           7.8                                                           
    Range                             --                    4--14                                                         5--14                                                         
  Mortality during follow-up, n (%)   10 (17.5)             2 (9.1)                                                       8 (22.9)                                                      
  No follow-up, n (%)                 2 (5.7)               0 (0.0)                                                       2 (5.7)                                                       

AM and EEC

EEC only. AM, adenomyosis uteri; EEC, endometrioid endometrial cancer; FIGO, International Federation of Gynaecology and Obstetrics.

###### 

Expression of the different proteins in the different groups.

  Protein                                All patients   Group A^[a](#tfn3-ol-0-0-6592){ref-type="table-fn"}^   Group B^[b](#tfn4-ol-0-0-6592){ref-type="table-fn"}^   P-value
  -------------------------------------- -------------- ------------------------------------------------------ ------------------------------------------------------ ---------
  Estrogen receptor β (IRS \>2), n (%)                                                                                                                                \<0.001
    Yes                                  7 (12.7)       6 (30.0)                                               1 (2.9)                                                
    No                                   48 (87.3)      14 (70.0)                                              34 (97.1)                                              
  Glycodelin (IRS \>2), n (%)                                                                                                                                         0.028
    Yes                                  38 (86.4)      15 (78.9)                                              23 (92.0)                                              
    No                                   6 (13.6)       4 (21.1)                                               2 (8.0)                                                
  Inhibin βB (IRS \>2), n (%)                                                                                                                                         0.077
    Yes                                  34 (94.4)      14 (93.3)                                              20 (95.2)                                              
    No                                   2 (5.5)        1 (6.7)                                                1 (4.8)                                                

AM and EEC

EEC only. AM, adenomyosis uteri; EEC, endometrioid endometrial cancer; IRS, immunoreactivity score.
